Observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). Pancreatitis: Has been reported in clinical trials.Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic ® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist. If hypersensitivity reactions occur, discontinue use of Ozempic ® treat promptly per standard of care, and monitor until signs and symptoms resolve. Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported in patients treated with Ozempic ®.Monitor renal function when initiating or escalating doses of Ozempic ® in patients reporting severe adverse gastrointestinal reactions. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. ![]() Some of these events have been reported in patients without known underlying renal disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |